Show simple item record

dc.contributor.authorHawkins, Robert; email: robert.e.hawkins@manchester.ac.uk
dc.contributor.authorFife, Kate
dc.contributor.authorHurst, Michael
dc.contributor.authorWang, Meng
dc.contributor.authorNaicker, Niroshini
dc.contributor.authorNolasco, Sarah
dc.contributor.authorEisen, Tim
dc.contributor.authorMatakidou, Athena
dc.contributor.authorGordon, Jason
dc.date.accessioned2021-07-20T13:49:44Z
dc.date.available2021-07-20T13:49:44Z
dc.date.issued2020-07-17
dc.date.submitted2020-03-23
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625301/12885_2020_Article_7154_nlm.xml?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625301/additional-files.zip?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625301/12885_2020_Article_7154.pdf?sequence=4
dc.identifier.citationBMC Cancer, volume 20, issue 1, page 670
dc.identifier.urihttp://hdl.handle.net/10034/625301
dc.descriptionFrom Springer Nature via Jisc Publications Router
dc.descriptionHistory: received 2020-03-23, accepted 2020-07-08, registration 2020-07-09, pub-electronic 2020-07-17, online 2020-07-17, collection 2020-12
dc.descriptionPublication status: Published
dc.descriptionFunder: Bristol Myers Squibb Pharmaceuticals Ltd.
dc.description.abstractAbstract: Background: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus, this study aimed to determine the effectiveness of targeted systemic therapies for patients with mRCC in routine clinical practice in the UK. Methods: A retrospective, observational, longitudinal study based on chart review of newly diagnosed adult mRCC patients treated at two UK hospitals from 2008 to 2015 was conducted. Targeted systemic therapies recommended for use in mRCC patients were evaluated across first to third lines of therapy (1LOT-3LOT). Important exclusions were treatment with cytokine therapy and within non-standard of care clinical trials. Primary outcome measure was overall survival (OS); data were analysed descriptively and using Kaplan-Meyer analysis. Results: 652 patients (65.3% male, 35.0% ≥70 years) were included. In 1LOT, 98.5% of patients received sunitinib or pazopanib. In 2LOT and 3LOT, 99.0 and 94.4% received axitinib or everolimus. Median OS was 12.9, 6.5 and 5.9 months at 1LOT, 2LOT and 3LOT respectively. Estimated OS at 1-year was 52.4% (95% CI: 48.6–56.4%) in 1LOT, 31.5% (25.2–39.5%) in 2LOT and 23.8% (10.1–55.9%) in 3LOT. Median OS from 1LOT in favourable, intermediate and poor MSKCC were 39.7, 15.8 and 6.1 months respectively. Conclusions: In this study, treatment was consistent with current National Institute for Health and Care Excellence (NICE) guidelines for mRCC patients. Although the study population favoured poorer prognosis patients, outcomes were more favourable than those for England at the same time. However, overall survival in this ‘real-world’ population remains poor and indicates significant unmet need for effective and safe treatment options to improve survival among mRCC patients.
dc.languageen
dc.publisherBioMed Central
dc.rightsLicence for this article: http://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 1471-2407
dc.subjectResearch Article
dc.subjectMedical and radiation oncology
dc.subjectRenal Cancer
dc.subjectMolecular targeted therapy
dc.subjectSurvival analysis
dc.titleTreatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK
dc.typearticle
dc.date.updated2021-07-20T13:49:44Z
dc.date.accepted2020-07-08


Files in this item

Thumbnail
Name:
12885_2020_Article_7154_nlm.xml
Size:
68.63Kb
Format:
XML
Thumbnail
Name:
additional-files.zip
Size:
328.9Kb
Format:
Unknown
Thumbnail
Name:
12885_2020_Article_7154.pdf
Size:
1.944Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record